Does Insurance Cover Ozempic?

1. The GLP-1 drug landscape

“GLP-1 agonists” are a class of medications originally developed for Type 2 diabetes that turned out to have significant weight loss effects. The result: a confusing landscape of brand names that are sometimes the same drug for different uses.

The pattern: same drug, different brands

Ozempic and Wegovy contain the same active ingredient (semaglutide) at similar doses. Mounjaro and Zepbound contain the same active ingredient (tirzepatide). The drugs are branded separately so manufacturers can list them at different prices, with different prior authorization rules, and with FDA approval limited to a specific use. This dual-branding is exactly why coverage gets so complicated.

2. Two paths: diabetes coverage vs weight loss coverage

The single most important factor in GLP-1 coverage is what your prescription is treating.

Path 1: Type 2 diabetes (typically covered)

If you have a documented Type 2 diabetes diagnosis and your physician prescribes Ozempic, Mounjaro, Rybelsus, or Victoza, most plans cover it with prior authorization. Typical coverage requirements:

• Confirmed T2D diagnosis (A1C 6.5%+ or established history)
• Documentation of prior treatment attempts (often metformin first-line)
• BMI documentation (sometimes required)
• No contraindicated medical conditions

Once approved, copays vary by plan and tier:

• Tier 2 (preferred brand): $30–$80/month copay typically
• Tier 3 (non-preferred brand): $80–$200/month copay
• Tier 4 (specialty): 25–40% coinsurance, sometimes $250–$500/month

Path 2: Weight loss (much harder)

When prescribed for weight management without a T2D diagnosis, coverage is dramatically more restrictive:

• Most employer plans now exclude GLP-1s for weight loss (cost-driven shift starting 2024-2025)
• Most ACA Marketplace plans don’t cover weight loss medications at all
• Medicare Part D is statutorily prohibited from covering weight loss drugs (could change with future legislation)
• State Medicaid programs vary — some cover Wegovy/Zepbound for weight management with criteria; others don’t

For weight loss-specific brands (Wegovy, Zepbound, Saxenda), when coverage is available, typical criteria mirror bariatric surgery:

• BMI 30+ with at least one weight-related comorbidity, OR
• BMI 27+ with cardiovascular risk factors (newer FDA criteria for Wegovy)
• Documented prior weight loss attempts
• Concurrent lifestyle modification program

3. ACA Marketplace coverage reality

The ACA’s 10 Essential Health Benefits include “prescription drugs” but don’t mandate coverage of specific medications. Each state’s benchmark plan determines what drugs are required to be covered, and within that, each plan has its own formulary.

For Type 2 diabetes

Most ACA Marketplace plans cover Ozempic and Mounjaro as Tier 2 or Tier 3 brand-name medications when prescribed for T2D. Prior authorization is virtually universal. Step therapy (try cheaper drugs first) is increasingly common — you may need to try and fail metformin and a sulfonylurea before getting Ozempic approved.

For weight loss

Most ACA Marketplace plans do NOT cover weight loss medications. The federal benchmark plan doesn’t require it, and few states have added it. Some standalone exceptions exist but they’re the minority. If you’re shopping for an ACA plan specifically to get weight loss medications covered, expect disappointment in most markets.

What to check before enrolling

• Pull the plan’s formulary (drug list) and search for “semaglutide,” “tirzepatide,” “Wegovy,” “Zepbound”
• Check what tier the drug is on (Tier 4 = expensive even when covered)
• Note if there are quantity limits, prior auth, or step therapy requirements
• Verify your specific dose/strength is covered

4. Employer plan coverage

Employer plan coverage of GLP-1s has been the central drama of pharmacy benefits in 2024–2026. Many large employers added Wegovy and Zepbound to their formularies in 2023–2024 only to remove or restrict coverage as drug spending exploded.

What’s happened

• Employer pharmacy spending on GLP-1s skyrocketed — some employers reported these drugs accounting for 10–15%+ of total pharmacy budget
• Many employers have moved to exclude GLP-1s for weight loss (Connecticut state employees, North Carolina state employees, RTX, Mayo Clinic and others have made this transition)
• Some employers maintain coverage with strict criteria: BMI 35+, comorbidity required, mandatory lifestyle program participation, quantity limits
• Self-insured plans have full discretion to include or exclude weight loss drugs (most large employers are self-insured)

What employers typically still cover

• Ozempic, Mounjaro, Rybelsus, Victoza for confirmed Type 2 diabetes (usually with PA)
• Saxenda for chronic weight management at fewer plans
• Wegovy and Zepbound for weight loss at a shrinking minority of plans, usually with strict criteria

What to do if your employer plan denied coverage

1. Verify your plan’s exact formulary policy for the specific drug
2. If denied based on diagnosis, talk to your physician about whether T2D criteria can be appropriately documented (only if medically accurate)
3. Check if any related conditions covered by the drug (sleep apnea coverage was added to Zepbound in late 2024) apply to you
4. Appeal with strong physician documentation if you believe the denial was incorrect
5. Explore patient assistance programs as a fallback

5. Medicare and Medicaid coverage

Medicare Part D

Medicare Part D covers GLP-1s for Type 2 diabetes with prior authorization. Copays vary by plan and tier — typically $30–$200/month or 25–33% coinsurance depending on tier placement.

Medicare is legally prohibited from covering medications “used for the treatment of obesity” or weight loss by a 2003 statute (the Medicare Modernization Act). This means Wegovy, Zepbound, and Saxenda cannot be covered by Medicare Part D for weight loss purposes. However, when these drugs receive FDA approval for related medical conditions (e.g., Wegovy’s 2024 approval for cardiovascular risk reduction in some adults, Zepbound’s 2024 approval for obstructive sleep apnea), Medicare may cover them for those specific approved indications. There’s ongoing congressional discussion about changing the weight loss exclusion.

Medicaid

State Medicaid programs handle GLP-1 coverage very differently:

• Type 2 diabetes: Generally covered across all state Medicaid programs with PA
• Weight loss: Coverage varies dramatically. A growing number of states cover Wegovy or Zepbound through Medicaid for adults meeting clinical criteria. Many states still don’t. The list is changing — check your state’s most current Medicaid Preferred Drug List.

6. The prior authorization process

Prior authorization (PA) is universal for GLP-1 medications. Understanding the process helps you get approved faster.

How PA works

1. Your physician submits a PA request to your insurance/PBM with clinical documentation
2. The PBM reviews documentation against the plan’s coverage criteria
3. Decision returned within 24–72 hours typically (urgent: 24 hours; standard: up to 14 days)
4. If approved, prescription processes at pharmacy
5. If denied, written denial with appeal rights

What documentation strengthens a PA request

• For T2D: Recent A1C results showing diagnosis, prior medication history (metformin trial if applicable), comorbidity documentation
• For weight loss: BMI documentation over time, comorbidity diagnoses with ICD-10 codes, prior weight loss attempts documented, blood pressure/lipid panel showing cardiovascular risk
• Statement of medical necessity from prescriber addressing plan-specific criteria

What gets denials

• Diagnosis doesn’t match drug’s FDA-approved indication
• Missing trials of cheaper therapy (step therapy violation)
• BMI documentation insufficient or below threshold
• Off-label use (Ozempic prescribed for weight loss instead of Wegovy)
• Missing supporting clinical notes

How to appeal a denial

Federal law requires insurers to provide an appeals process. Most appeals can include:

1. Internal appeal to the insurance company (typically 30-day window from denial)
2. External review by an independent organization if internal appeal fails
3. Expedited appeals if there’s urgent medical need

Many GLP-1 denials are overturned on appeal when documentation is strengthened. Your physician’s office can typically help with the appeal letter.

7. Cost without insurance

These are approximate retail cash prices. Actual cash prices vary by pharmacy and region, and change frequently as manufacturers respond to market conditions. GoodRx, SingleCare, and other discount cards can shave 10–20% off retail. Big-box pharmacy memberships (Costco, Sam’s Club) sometimes offer better pricing for cash payers.

8. Patient assistance and savings options

If your insurance doesn’t cover the drug, several options can significantly reduce the cash cost:

Manufacturer savings cards

• Novo Nordisk: Ozempic, Wegovy, Rybelsus, Saxenda all have savings cards reducing costs for commercially-insured patients (cards do not apply to Medicare, Medicaid, or other federal programs)
• Eli Lilly: Mounjaro and Zepbound savings cards similarly available for commercially-insured patients

These cards typically bring covered prescriptions down to $25–$200/month for eligible patients. Critically: the card requires commercial insurance coverage to work. If your insurance doesn’t cover the drug at all, the savings card doesn’t apply.

Patient Assistance Programs (PAPs)

Both Novo Nordisk and Eli Lilly run Patient Assistance Programs for low-income patients without insurance or with significant coverage gaps. Income eligibility is typically 400% FPL or below, and assistance can provide medication at no cost or significantly reduced cost. Applications require documentation of income, residency, and lack of coverage.

LillyDirect (Lilly’s direct-to-patient program)

Eli Lilly offers Zepbound at reduced cash prices through LillyDirect, with some doses available at meaningfully lower prices than retail pharmacy. Verify current pricing at the official LillyDirect site.

Wegovy direct from Novo Nordisk

Novo Nordisk introduced a NovoCare Pharmacy direct-pay option for Wegovy at a lower price point than retail cash for self-pay patients. Verify current pricing and eligibility at the official NovoCare site.

Switch insurance plans during Open Enrollment

If your current plan doesn’t cover your medication, switching to one that does during Open Enrollment (Nov 1 – Jan 15) can dramatically change your cost. Verify the new plan’s formulary explicitly covers your medication before switching.

Telehealth platforms

Several telehealth companies (Ro, Hims, Sequence/Weight Watchers, others) offer prescription evaluation and access to brand-name or some compounded GLP-1s. Costs vary widely; quality of medical oversight varies. Patients should verify the prescribing clinician is properly licensed and that medication sources are FDA-regulated.